Usefulness of Short-Term Imaging and Squamous Cell Carcinoma Antigen to Early Predict Response to Concurrent Chemoradiotherapy in Patients With Cervical Cancer

Ji Geun Yoo, MD\textsuperscript{1,}\textsuperscript{a}, Sang Il Kim, MD, PhD\textsuperscript{2,}\textsuperscript{a}, Seung Geun Yeo, MD, PhD\textsuperscript{3}, and Dong Choon Park, MD, PhD\textsuperscript{2,}\textsuperscript{a}

Abstract

Objective: The objective is to investigate the factors that can predict early treatment response in patients receiving concurrent chemoradiotherapy (CCRT) for cervical cancer.

Methods: We assessed clinical factors and treatment response in patients who underwent CCRT for cervical cancer at four time points: initial, 2.5 weeks, 6 weeks after starting CCRT, and 3 months after completing CCRT. The final treatment response was determined by positron emission tomography-computed tomography (PET-CT) 3 months after completion of CCRT. Patients were divided into two groups according to the final treatment response: complete response (CR) group or non-CR group. And the early CCRT response prediction model was developed using stepwise multivariate logistic regression analysis.

Results: Of the 62 patients who underwent CCRT for cervical cancer, 57 patients who completed all 4 time points examinations were included in the analyses and classified as CR (n = 32) and non-CR (n = 25) group. Tumor volume and serum squamous cell carcinoma antigen (SCC Ag) of the initial, 2.5 weeks, and 6 weeks after CCRT were significantly associated with the final treatment response. For the early treatment response prediction model, we selected patient age, tumor volume, and SCC Ag measured at initial and 2.5 weeks of CCRT as variables, and the equation of the final model was yielded. Using a cutoff of 0.433, this model had a sensitivity of 72.0%, a specificity of 84.4%, and a probability of 0.8225 ($P < .0001$).

Conclusion: Short-term (at 2.5 weeks after starting CCRT) measurements of tumor volume and serum SCC Ag were significant predictors of response to CCRT in patients with cervical cancer.

Keywords
cervical cancer, chemoradiation, prediction, MRI, SCC

Introduction

Concurrent chemoradiotherapy (CCRT) is regarded as the definitive standard treatment for patients with locally advanced cervical cancer.\textsuperscript{1,2} Overall response rates to cisplatin-based CCRT are over 90%,\textsuperscript{3,4} and 3-year disease-free survival (DFS) rates have been reported to range from 65% to 75%.\textsuperscript{5,6} However, 30% to 50% of cervical cancer patients who receive CCRT experience treatment failure,\textsuperscript{5} with locoregional recurrence being the main

---

\textsuperscript{1}Department of Obstetrics and Gynecology, Daejeon St Mary's Hospital, The Catholic University of Korea, Daejeon, South Korea
\textsuperscript{2}Department of Obstetrics and Gynecology, St Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea
\textsuperscript{3}Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University, Seoul, South Korea

Corresponding Author:
Dong Choon Park, Department of Obstetrics and Gynecology, Saint Vincent's Hospital, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do 16247, South Korea.
Email: park.dongchoon@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
cause of failure. Large tumor size and lymph node involvement are factors contributing to recurrence.9,10 Moreover, discontinuation of radiation dose, addition of other chemotherapeutic agents, or enrollment in clinical trials.9-11 Moreover, discontinuation of ineffective treatment can reduce associated toxicity and morbidity.12

Magnetic resonance imaging (MRI) was found to be optimal in the radiologic assessment of cervical cancer, playing significant roles in initial staging, as well as guiding primary treatment and evaluating treatment response.13 Moreover, the serum concentration of squamous cell carcinoma antigen (SCC Ag), a biomarker of cervical cancer, has been used to predict outcomes and responses to therapy, as well as to detect early recurrence during posttreatment surveillance.11,14

The present study was designed to identify potential markers predicting the failure of CCRT in patients with cervical cancer and to determine whether a combination of MRI and SCC Ag measurement could predict early treatment failure in cervical cancer patients treated with CCRT.

Materials and Methods

The study protocol was approved by the institutional review board of the Catholic University of Korea St. Vincent’s Hospital, which waived the requirement for informed consent due to the retrospective nature of the study (VC17RESI0154). The reporting of this study conforms to the reporting recommendations for tumor marker prognostic studies (REMARK) guidelines.15

Patients and Tumor Characteristics

This retrospective study enrolled patients with histologically confirmed squamous cell carcinoma of the uterine cervix who were scheduled to receive definitive CCRT between July 2012 and December 2016 at our hospital. Clinical data were collected from patients’ electronic medical records, with all patient data anonymized to maintain patient confidentiality. Each patient was staged according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO).16 Patients were included if they were aged ≥21 years, had FIGO stage IB2 to IVA tumors, and had no history of prior chemotherapy or radiotherapy.

CCRT Treatment

All patients were treated with a combination of concurrent radiotherapy and chemotherapy. Radiotherapy consisted of computed tomography (CT)-guided external beam radiotherapy (EBRT) and intracavitary high-dose-rate brachytherapy (ICR). The total dose of EBRT delivered to the whole pelvis was 50 Gy, in doses of 2 Gy/day, five days per week for 5 weeks. Chemotherapy consisted of 50 mg/m² cisplatin once weekly for four or five weeks. At the end of EBRT, ICR was initiated at a dose of 5 Gy delivered to point A, defined according to the guidelines of the American Brachytherapy Society,17 twice weekly for 3 weeks, for a total dose of 30 Gy. Patients completed CCRT within 8 weeks.

Evaluation of Treatment Response

All patients underwent positron emission tomography-computed tomography (PET-CT) at two time points: before initiation of CCRT to evaluate nodal and/or extrapelvic tumors, and 3 months after the completion of CCRT to evaluate the final response to treatment. Patients underwent MRI, and the concentrations of tumor markers (SCC Ag and CEA) were measured, at four time points: before initiation of CCRT (baseline), 2.5 weeks and 6 weeks after starting treatment, and 3 months after completing CCRT. Response to CCRT was determined by assessing tumor volumes measured by MRI 3D volumetry at these time points. All MRIs were performed using a 3.0-T MRI scanner (Siemens Magnetom Verio, Achieva 3.0 T, Philips Healthcare, The Netherlands), with a 16-channel torso phased-array body coil. Two radiologists independently evaluated the longest tumor diameter based on T2-weighted images at maximal and, after comparing their results, reached consensus. Tumor volume was calculated by multiplying the longest horizontal, vertical, and height diameters, and π/6.18 Serum SCC Ag was measured by immunoradiometric assay using the ARCHITECT SCC Reagent Kit (Abbott Diagnostics, Chicago, IL, USA). Clinical responses based on PET-CT scans performed 3 months after the end of CCRT were determined using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.19 Responses were classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). Patients were divided into two groups, those who achieved CR and those who did not, with the non-CR group including patients with PR, PD, and SD.

Statistical Analysis

Continuous variables were expressed as mean and standard deviation (SD) and compared using unpaired two-sample Student’s t-tests, whereas categorical variables were expressed as numbers and percentages and compared using chi-square tests. Variables associated with CR were evaluated by logistic regression analysis, with the resulting predictive model validated by receiver operating characteristics (ROC) curve analysis. Interobserver and intra-observer agreements were assessed by calculating intra-class correlation coefficients (ICCs) with 95% confidence internals (CI). Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA.). A two-sided P-value < .05 was defined as statistically significant.
Results

Patients and Tumor Characteristics

Of the 62 patients enrolled in this study, five were excluded because follow-up clinical evaluations were incomplete. The characteristics of the 57 included patients are summarized in Table 1. PET-CT scans performed 3 months after the end of CCRT showed that 32 (56.1%) patients achieved CR, whereas 25 (43.9%) did not; this non-CR group included 22 (38.6%) patients who achieved PR and three (5.3%) with SD or PD.

Prior to treatment, the mean tumor volume was 32.8 cm³ in the CR group and 73.1 cm³ in the non-CR group ($P = .035$).

Early CCRT Response Prediction Model: The CCRT Complete Response Index

The early CCRT response prediction model was developed using stepwise multivariate logistic regression analysis. Only clinical variables that are routinely measured and correlated

| Table 1. Demographic and Clinical Characteristics of Patients in the CR and Non-CR Groups. |
|-------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Factor                               | Total (N = 57) | CR Group (n = 32) | Non-CR Group (n = 25) | P               |
|-------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Age                                     | 59.1 (13.2)     | 56.5 (12.6)     | 62.4 (13.3)     | .091            |
| BMI, kg/m²                               | 24.2 (4.74)     | 25.3 (5.5)      | 22.9 (3.2)      | .066            |
| Hypertension                             | 16 (28.1%)      | 9 (28.1%)       | 7 (28.0%)       | >.999           |
| Diabetes                                 | 6 (10.5%)       | 4 (12.5%)       | 2 (8.0%)        | .686            |
| FIGO stage                               | 38 (66.7%)      | 22 (68.8%)      | 16 (64.0%)      | .024            |
| IB2                                      | 6 (10.5%)       | 6 (18.8%)       | 0               |                 |
| II                                       | 38 (66.7%)      | 22 (68.8%)      | 16 (64.0%)      |                 |
| III                                      | 4 (7.0%)        | 2 (6.3%)        | 2 (8.0%)        |                 |
| IVA                                      | 9 (15.8%)       | 2 (6.3%)        | 7 (28.0%)       |                 |
| Differentiation                          |                 |                 |                 | >.999           |
| Well                                     | 13 (22.8%)      | 7 (21.9%)       | 6 (24.0%)       |                 |
| Moderate                                 | 38 (66.7%)      | 21 (65.6%)      | 17 (68.0%)      |                 |
| Poor                                     | 1 (1.8%)        | 1 (3.1%)        | 0               |                 |
| Not available                            | 5 (8.8%)        | 3 (9.4%)        | 2 (8.0%)        |                 |
| Lymph node metastasis*                   | 30 (52.6%)      | 14 (43.8%)      | 16 (64.0%)      | .183            |
| Tumor volume, cm³                        | 50.5 (54.9)     | 32.8 (24.5)     | 73.1 (72.8)     | .035            |
| Initial                                  |                 |                 |                 |                 |
| CCRT 2.5 wksb                             | 9.5 (16.2)      | 3.5 (5.2)       | 17.2 (21.6)     | <.001           |
| CCRT 6 wksb                              | 4.3 (11.0)      | 0.9 (2.2)       | 8.7 (15.5)      | <.001           |
| SCC Ag, ug/ml                            | 14.4 (19.2)     | 9.5 (14.9)      | 20.8 (22.4)     | .010            |
| Initial                                  | 8.7 (14.2)      | 4.9 (8.3)       | 13.5 (18.4)     | .003            |
| CCRT 6 wksb                              | 1.85 (2.0)      | 1.3 (0.9)       | 2.5 (2.6)       | .017            |
| Initial laboratory findings              |                 |                 |                 |                 |
| White blood cells, /µL                   | 8197.6 (2117.6) | 7693.0 (2232.3) | 8803.2 (1835.1) | .052            |
| Hemoglobin, g/dL                         | 12.0 (1.8)      | 12.4 (1.6)      | 11.5 (1.9)      | .066            |
| Hematocrit, %                            | 35.7 (4.9)      | 36.6 (4.2)      | 34.6 (5.5)      | .125            |
| CEA, ng/mL                               | 5.3 (6.2)       | 6.1 (7.5)       | 4.2 (3.9)       | .303            |
| Clinical response 3 months after completion of CCRT |  | | | |
| Complete response                         | 32 (56.1%)      | 32 (100%)       | 0               |                 |
| Partial response                          | 22 (38.6%)      | 0               | 22 (88.0%)      |                 |
| Stable disease or disease progression     | 3 (5.3%)        | 0               | 3 (12.0%)       |                 |

Footnote: All values are expressed as the mean (SD) or number (%).

CR, complete response; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; SCC Ag, squamous cell carcinoma antigen; CEA, carcinoembryonic antigen; CCRT, concurrent chemoradiotherapy.

*Positive on radiologic workup at the time of initial diagnosis.

b2.5 wks and 6 wks indicate the time points from the initiation of CCRT.
with CCRT outcomes were selected for the development of the prediction model. The variables showing the highest correlation with the outcome of CCRT and predictable at the earliest time point were selected. These variables included tumor volumes and SCC Ag concentrations at baseline (initial) and 2.5 weeks after starting CCRT (Table 2). Age was also entered into the model as a demographic characteristic and as a fixed variable, and all other variables were sequentially entered into the model using the forward likelihood ratio method (Table 3). The logit value derived from the final model for each subject was calculated, and the probability for CR, which was calculated from the logit value, was called the CCRT CR index (CCRT CRI). Using this index, ROC curve analysis was performed, and the area under the curve (AUC) was calculated (Figure 1). Because the optimal cutoff point for CCRT CRI

Table 2. Univariate Analysis of the Clinical Variables.

| Predictive Variable | Beta   | Wald Value | OR (95% CI)     | P   |
|---------------------|--------|------------|-----------------|-----|
| Initial tumor volume| 0.019  | 5.319      | 1.019 (1.003–1.036) | .021 |
| Initial SCC Ag      | 0.035  | 4.143      | 1.036 (1.001–1.072) | .042 |
| Tumor volume at 2.5 wks of CCRTa| 0.121  | 6.370      | 1.128 (1.027–1.239) | .012 |
| SCC Ag at 2.5 wks of CCRTa | 0.068  | 3.429      | 1.070 (0.996–1.150) | .046 |
| Tumor volume at 6 wks of CCRTa | 0.247  | 4.119      | 1.280 (1.008–1.624) | .042 |
| SCC Ag at 6 wks of CCRTa | 0.532  | 4.393      | 1.702 (1.035–2.800) | .036 |
| FIGO stage (III-IVA vs IB2-II) | 1.371  | 3.937      | (1.043–14.863) | .043 |

Footnote: OR, odds ratio; SCC Ag, squamous cell carcinoma antigen; CCRT, concurrent chemoradiotherapy; FIGO, International Federation of Gynecology and Obstetrics.

a2.5 wks and 6 wks indicate the time points from the initiation of CCRT.

Table 3. The AUC Values of ROC Curves for Prediction Models for Complete Response Determined 3 Months after Completing CCRT.

| Predictive Model | Crude Model | Age Adjusted Model |
|------------------|-------------|--------------------|
| Initial TV, initial SCC | 0.695 (0.550-0.840) | 0.785 (0.666-0.904) |
| 2.5 wks TV, 2.5 wks SCCa | 0.780 (0.660-0.900) | 0.818 (0.705-0.930) |
| 6 wks TV, 6 wks SCCa | 0.785 (0.658-0.912) | 0.814 (0.701-0.927) |
| Initial TV, initial SCC, 2.5 wks TV, 2.5 wks SCCa | 0.778 (0.656-0.899) | 0.823 (0.711-0.934) |
| Initial TV, initial SCC, 2.5 wks TV, 2.5 wks SCC, stagea | 0.778 (0.656-0.899) | 0.821 (0.710-0.932) |
| Initial TV, initial SCC, 6 wks TV, 6 wks SCCa | 0.814 (0.700-0.928) | 0.831 (0.725-0.938) |
| Initial TV, initial SCC, 6 wks TV, 6 wks SCC, stagea | 0.804 (0.687-0.920) | 0.828 (0.720-0.935) |

Footnote: CCRT, concurrent chemoradiotherapy; TV, tumor volume; SCC, squamous cell carcinoma antigen. The AUC values were presented with the 95% CI.

Table 4. Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy at Various Cutoff Points for CCRT CRI.

| Cutoff | Youden | Sensitivity | Specificity | PPV | NPV | Accuracy |
|--------|--------|-------------|-------------|-----|-----|----------|
| ≥0.1   | 1.03   | 1.00        | 0.03        | 1.00| 0.03| 0.46     |
| ≥0.2   | 1.27   | 0.96        | 0.31        | 0.96| 0.31| 0.60     |
| ≥0.3   | 1.40   | 0.84        | 0.56        | 0.84| 0.56| 0.68     |
| ≥0.4   | 1.50   | 0.72        | 0.78        | 0.72| 0.78| 0.75     |
| ≥0.5   | 1.48   | 0.60        | 0.88        | 0.60| 0.88| 0.75     |
| ≥0.6   | 1.36   | 0.48        | 0.88        | 0.48| 0.88| 0.70     |
| ≥0.7   | 1.28   | 0.40        | 0.88        | 0.40| 0.88| 0.67     |
| ≥0.8   | 1.29   | 0.32        | 0.97        | 0.32| 0.97| 0.68     |
| ≥0.9   | 1.04   | 0.04        | 1.00        | 0.04| 1.00| 0.58     |

Footnote: CCRT CRI, concurrent chemoradiotherapy complete response index; PPV, positive predictive value; NPV, negative predictive value.

2.5 weeks after starting CCRT (Table 2). Age was also entered into the model as a demographic characteristic and as a fixed variable, and all other variables were sequentially entered into the model using the forward likelihood ratio method (Table 3). The logit value derived from the final model for each subject was calculated, and the probability for CR, which was calculated from the logit value, was called the CCRT CR index (CCRT CRI). Using this index, ROC curve analysis was performed, and the area under the curve (AUC) was calculated (Figure 1). Because the optimal cutoff point for CCRT CRI
was dependent on the purpose and setting of its use, changes in sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were assessed as the CCRT CRI increased from 0.1 to 0.9 in 0.1 unit steps, rather than determining a single optimal cutoff value for CCRT CRI (Table 4). External validation of the final model yielded the equation: Logit_model = -4.5767 + 0.0515 (age) + 0.00572 (initial tumor volume) - 0.00043 (initial SCC Ag concentration) + 0.0373 (tumor volume at 2.5 weeks) + 0.00297 (SCC Ag at 2.5 weeks). Using a cutoff of 0.4339, this model had a sensitivity of 72.0% and a specificity of 84.4%, with ROC curve analysis confirming a probability of 0.8225 (P < .0001).

Discussion

The standard treatment for locally advanced cervical cancer is CCRT followed by brachytherapy. It has been recommended that the entire treatment course be completed within 8 weeks to avoid treatment failure.1,2 Response to treatment is evaluated 3 months after the end of CCRT20 or 19–20 weeks after the start of treatment.2 During this time, however, patients who do not respond well to CCRT may miss the opportunity to receive an effective alternative treatment and may be exposed to toxicity and morbidity from unnecessary treatment. Therefore, early prediction of response to CCRT is important for optimizing treatment of poor responders.9,10,21 Completion hysterectomy after chemoradiation, although not widely performed, may enhance survival in patients with residual disease after CCRT.22-24 The OUTBACK trial (NCT01414608), an ongoing international randomized phase III trial, is expected to determine the efficacy and toxicity of adjuvant chemotherapy following CCRT.

The present study evaluated the ability of a combination of MRI 3D volumetry and serum SCC Ag concentration to predict response to CCRT. Several studies have assessed the optimal timing of MRI to measure tumor volume or tumor regression rate during CCRT as a predictor of treatment outcome. For example, tumor regression rate, as determined by sequential MRI measurements of tumor volume 4–5 weeks after the start of radiation treatment (40–50 Gy), was shown to be a sensitive method of assessing response to radiation therapy.21,25-27 Although earlier prediction can improve the ability to choose an appropriate alternative treatment, measuring the tumor regression rate at an earlier time point, 2–2.5 weeks after the start of treatment (20–24 Gy), showed inconsistent results. Tumor regression rate measured at 2–2.5 weeks did not correlate with treatment response or local recurrence rate, perhaps because morphologic changes in tumors in response to CCRT occur later than changes at the cellular/molecular level.25,27 In contrast, another study found that both tumor volume and tumor regression rate after 2–2.5 weeks of radiotherapy could predict local control and disease specific survival rate, although results after 4–5 weeks of treatment were better predictors of these outcomes.21

Inclusion of serum SCC Ag concentration in the algorithm improved the accuracy of predicting CR after 2–2.5 weeks of radiotherapy. SCC Ag is an important biomarker of cervical cancer,28 with elevated serum SCC Ag level being associated with advanced tumor stage, larger tumor size, lymphovascular and regional nodal involvement, and deep stromal involvement.29 Pre- and posttreatment SCC Ag concentrations, as well as its rate of reduction during CCRT, are useful predictors of treatment failure or survival outcomes in patients with cervical cancer.30-34 For example, normalization of serum SCC levels at the end of RT or a >70% reduction in concentration at 4 weeks correlated significantly with CR in patients with elevated pretreatment levels of serum SCC.35 Moreover, failure of serum SCC Ag to normalize to <2.2 ng/mL, after 4 weeks of CCRT was shown to be an early indicator of positive posttreatment FDG-PET.11 However, the ability of SCC Ag after 2–2.5 weeks of CCRT to predict CR has not yet been determined. The present study found that serum SCC Ag concentrations measured before treatment and after 2.5 weeks of CCRT correlated with CR rate 3 months after the end of treatment. A review of 304 patients with cervical SCC treated with CCRT found that the recurrence-free survival rates in patients with pretreatment SCC Ag levels <4 ng/mL and ≥4 ng/mL were 80.2% and 56.6%, respectively (P < .001).36 In addition, overall survival rates were lower and rates of local, regional, and distant metastases were higher in patients with elevated SCC Ag levels.36 Higher pretreatment SCC Ag levels were also found to be associated with para-aortic lymph node relapse after CCRT.37 Pretreatment SCC Ag levels have also been used to stratify risk in patients with cervical cancer.38,39 For example, an SCC Ag concentration >2 ng/mL was found to be an independent risk factor for distant failure. Patients with SCC Ag concentration <2 ng/mL, stage IB-IIIB disease, and negative lymph nodes were found to have a 5-year distant relapse-free survival rate of 83%, whereas those with SCC Ag >2 ng/mL, stage III disease, and positive lymph nodes had a 5-year distant relapse-free survival rate of 43%.39 Moreover, pretreatment SCC Ag level was shown to be independently prognostic of distant recurrence and was incorporated into a nomogram predicting the probability of distant recurrence within 5 years.38

The present study found that tumor volume and tumor marker concentrations were factors associated with outcomes after initiation of CCRT. Treatment response 3 months after the end of CCRT correlated with tumor volume and serum SCC Ag at initial and 2.5 weeks of CCRT. According to our Logit model, a cutoff value of 0.4339 yielded a sensitivity of 72.0% and a specificity of 84.4%. ROC curve analysis confirmed an AUC of 0.8225. These results were very close to the predicted value at the post-CCRT time point. This Logit model may predict early treatment failure in patients treated with CCRT for cervical cancer. The ability to predict treatment response before the end of treatment has
several advantages, as well as suggesting another potential marker for prediction of CCRT failure in patients with locally advanced cervical cancer.

This study had several limitations. First, the number of included patients was relatively small, suggesting the need for additional studies and target groups to improve the ability of the model to predict CR. Second, this study included only patients with the squamous cell type of cervical cancer, suggesting the need for studies on patients with other types of cervical cancer. Third, this predictive model was unable to clearly delineate a treatment modality for patients resistant to radiation therapy.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF 2019R1A2C1086807).

**Ethics Approval and Consent to Participate**

All Subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with Declaration of Helsinki, and the protocol was approved by the Ethics Committee of St Vincent’s Hospital (approval number: VC17RES10154).

**ORCID iDs**

Ji Geun Yoo \[https://orcid.org/0000-0001-5359-8729\]  
Sang Il Kim \[https://orcid.org/0000-0002-9987-698X\]  
Dong Choon Park \[https://orcid.org/0000-0001-9485-4987\]

**References**

1. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. *Int J Gynaecol Obstet*. 2018;143(suppl 2):22-36. doi:10.1002/ijgo.12611
2. National Comprehensive Cancer Network. *Cervical cancer (Version 1.2021)*. [https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf). Accessed September 22, 2021.
3. Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. *Gynecol Oncol*. 2008;108(1):195-200. doi:10.1016/j.ygyno.2007.09.022
4. Sol ES, Lee TS, Koh SB, Oh HK, Ye GW, Choi YS. Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma. *J Gynecol Oncol*. 2009;20(1):28-34. doi:10.3802/jgo.2009.20.1.28
5. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent cisplatin plus fluorouracil versus concurrent cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. *J Clin Oncol*. 2011;29(13):1678-1685. doi:10.1200/jco.2009.25.9663
6. Wang W, Zhang F, Hu K, Hou X. Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer. *Gynecol Oncol*. 2018;151(3):444-448. doi:10.1016/j.ygyno.2018.09.024
7. Kumar L, Gupta S. Integrating chemotherapy in the management of cervical cancer: A critical appraisal. *Oncology*. 2016;91(suppl 1):8-17. doi:10.1159/000447576
8. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*. 1999;340(15):1144-1153. doi:10.1056/nejm199904153401502
9. Yuh WT, Mayr NA, Jarjoura D, et al. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. *Invest Radiol*. 2009;44(6):343-350. doi:10.1097/RLI.0b013e3181a64ce9
10. Liu Y, Sun H, Bai R, Ye Z. Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study. *Radiat Oncol*. 2015;10:185. doi:10.1186/s13014-015-0493-6
11. Markovina S, Wang S, Henke LE, et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. *Br J Cancer*. 2018;118(1):72-78. doi:10.1038/bjc.2017.390
12. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. *Gynecol Oncol*. 2008;111(2):213-220. doi:10.1016/j.ygyno.2008.07.048
13. Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR imaging of cervical cancer. *Magn Reson Imaging Clin N Am*. 2017;25(3):635-649. doi:10.1016/j.mric.2017.03.007
14. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment. *Clin Chim Acta*. 2015;445:7-11. doi:10.1016/j.cca.2015.03.005
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer*. 2005;93(4):387-391. doi:10.1038/sj.bjc.6602678
16. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. *Int J Gynaecol Obstet*. 2009;105(2):107-108. doi:10.1016/j.ijgo.2009.02.009
17. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Peterit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. *Int J Radiat Oncol Biol Phys*. 2000;48(1):201-211. doi:10.1016/s0360-3016(00)00497-1
18. Narayan K, Fisher R, Bernshaw D. Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy. *International Journal of Gynecologic*
19. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. *Eur J Cancer*. 2016;62:132-137. doi:10.1016/j.ejca.2016.03.081

20. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. *JAMA*. 2007;298(19):2289-2295. doi:10.1001/jama.2007.19.2289

21. Wang JZ, Mayr NA, Zhang D, et al. Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. *Cancer*. 2010;116(21):5093-5101. doi:10.1002/cncr.25260

22. Decker MA, Burke JJ 2nd, Gallup DG, et al. Completion hysterectomy after radiation therapy for bulky cervical cancer stages IB, IIA, and IIB: complications and survival rates. *Am J Obstet Gynecol*. 2004;191(2):654-658; discussion 658-660. doi:10.1016/j.ajog.2004.05.076

23. Sun L, Sheng X, Jiang J, et al. Surgical morbidity and oncologic results after concurrent chemoradiation therapy for advanced cervical cancer. *Int J Gynaecol Obstet*. 2014;125(2):111-115. doi:10.1016/j.ijgo.2013.07.041

24. Yoshida K, Kajiyama H, Yoshihara M, et al. The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer. *Int J Clin Oncol*. 2020;25(2):384-390. doi:10.1007/s10147-019-01551-6

25. Mayr NA, Magnotta VA, Ehrhardt JC, et al. Usefulness of tumor volumetry by magnetic resonance imaging in assessing response to radiation therapy in carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys*. 1996;35(5):915-924. doi:10.1016/0360-3016(96)00230-1

26. Mayr NA, Taoka T, Yuh WT, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. *Int J Radiat Oncol Biol Phys*. 2002;52(1):14-22. doi:10.1016/s0360-3016(01)01808-9

27. Nam H, Park W, Huh SJ, et al. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. *Gynecol Oncol*. 2007;107(2):320-325. doi:10.1016/j.ygyno.2007.06.022

28. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. *Cancer*. 1977;40(4):1621-1628. doi:10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435;3.0.co;2-i

29. Fu J, Wang W, Wang Y, Liu C, Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. *Radiat Oncol*. 2019;14(1):146. doi:10.1186/s13014-019-1355-4

30. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioreponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. *Obstet Gynecol*. 2002;100(4):781-787. doi:10.1016/s0029-7844(02)02204-4

31. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. *Crit Rev Oncol Hematol*. 2008;66(1):10-20. doi:10.1016/j.critrevonc.2007.09.002

32. Yin M, Hou Y, Zhang T, et al. Evaluation of chemotherapy response with serum squamous cell carcinoma antigen level in cervical cancer patients: a prospective cohort study. *PLoS One*. 2013;8(1):e54969. doi:10.1371/journal.pone.0054969

33. Lee JH, Lee SW, Kim JR, et al. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01. *Gynecol Oncol*. 2017;147(3):577-584. doi:10.1016/j.ygyno.2017.09.036

34. Wang W, Liu X, Hou X, et al. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. *Gynecol Oncol*. 2019;155(2):224-228. doi:10.1016/j.gyngono.2019.09.003

35. Ohno T, Nakayama Y, Nakamoto S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. *Cancer*. 2003;97(12):3114-3120. doi:10.1002/cncr.11453

36. Choi KH, Lee SW, Yu M, Jeong S, Lee JW, Lee JH. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. *J Gynecol Oncol*. 2019;30(1):e1. doi:10.3802/jgo.2019.30.e1

37. Huang EY, Huang YJ, Chanchien CC, et al. Pretreatment carcinobryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. *Radiat Oncol*. 2012;7:13. doi:10.1186/1748-717X-7-13

38. Kang S, Nam BH, Park JY, et al. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study. *J Clin Oncol*. 2012;30(19):2369-2374. doi:10.1200/jco.2011.37.5923

39. Hong JH, Tsai CS, Lai CH, et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. *Int J Radiat Oncol Biol Phys*. 2005;63(2):492-499. doi:10.1016/j.ijrobp.2005.02.012